FDNA

Executive Summary

FDNA is a Boston-based digital health company that leverages artificial intelligence and computer vision to accelerate the diagnosis of developmental and genetic disorders. Its flagship platform, Face2Gene, is used by healthcare professionals in over 10,000 medical centers globally to analyze facial features and phenotypic data, aiding in the identification of hundreds of genetic syndromes. By connecting patients and providers with pharmaceutical companies and contract research organizations (CROs), FDNA serves as a data clearinghouse and decision-support tool, enabling faster diagnoses and improved care management. Founded in 2011, the company operates at the intersection of genetics, digital health, and AI, with a growing footprint in clinical genomics. FDNA's value proposition lies in its ability to reduce diagnostic odysseys for patients with rare diseases and to generate real-world evidence for pharma partners. The platform's growing database of phenotypic and genomic data positions it as a key asset for rare disease drug development and clinical trial recruitment. As the company continues to expand its AI capabilities and commercial partnerships, it is well-positioned to capture significant share in the precision medicine market. With no disclosed funding rounds or valuation, FDNA remains privately held, likely supported by revenue from its pharma services.

Upcoming Catalysts (preview)

• Q3 2026FDA Clearance for New AI Diagnostic Module60% success
• TBDMajor Pharma Partnership for Clinical Trial Recruitment50% success
• Q2 2026Publication of Key Validation Study in Peer-Reviewed Journal70% success